Navigation Links
Creation of antibiotic in test tube holds promise for better antibiotics

Scientists have made nisin, a natural antibiotic used for more than 40 years to preserve food, in a test tube for the first time using nature's toolbox. They also identified the structure of the enzyme that makes nisin and gives it its unique biological power.

The work -- published in the March 10 issue of Science -- sheds light on the almost magical manner in which nisin is made in nature and moves researchers closer to producing new antibiotics that would preclude the development and spread of antibiotic-resistant bacteria, said Wilfred A. van der Donk, a professor of chemistry, and Satish Nair, a professor of biochemistry, both at the University of Illinois at Urbana-Champaign.

Nisin, a peptide, contains 34 amino acid residues and the unusual amino acids lanthionine, methyllanthionine, dehydroalanine and dehydro-amino-butyric acid. The latter are made by post-translational modification of proteins.

Nisin works well against Gram-positive bacteria and food-borne pathogens that cause botulism and listeriosis because it punches holes into cell membranes and binds to essential molecules in the disease-causing bacteria. Hitting on at least two targets reduces the risk of resistance occurring, van der Donk said.

The researchers synthesized nisin simply in a test tube by using a single cyclase enzyme to re-create the process that normally occurs in a strain of the bacterium Lactococcus lactis found naturally in milk. They demonstrated how just one protein (NisC) makes 10 new chemical bonds in a stereochemically defined fashion. Specifically, they showed that NisC is responsible for the formation of five characteristic thioether rings required for nisin's biological activity.

"Despite all the progress in synthetic chemistry, we cannot come close to making a compound like nisin efficiently," van der Donk said. "Synthetic chemists in the past needed 67 steps to make it, while nature uses just two enzymes. One of these is the cyclase wh ose activity we have demonstrated in this paper."

The thioether rings vary in size from four to seven amino acids and provide sturdy protease-resistant bonds at precise locations. They account for nisin's robust resistance capability. It was theorized that one enzyme makes all five rings despite their very different sizes, but how it did so was like the mystery of a magic show, van der Donk said.

Nisin is one of numerous members of a family of compounds called lantibiotics, all of which are candidates for bioengineering into new pharmaceuticals, van der Donk said. The key is learning more about the enzymes involved in their biosynthesis. "Our work, while not explaining everything, has brought us much closer to that understanding, in particular the beautiful structure solved by the Nair group," he said.

Van der Donk previously had identified the molecular activity of another enzyme (LctM) responsible for naturally turning a small protein into a lantibiotic. That discovery, reported in Science in 2004, involved lacticin 481.

The new research also showed that NisC has unexpected structural similarities with mammalian farnesyl transferases, which are important for the activity of the RAS protein which when mutated is implicated in 25 percent of breast cancers. Preventing farnesylation possibly could prevent the cancerous effects, because the mutant protein would no longer be localized at the membrane, Nair said.

An accompanying Perspectives article in Science, written by chemist David W. Christianson of the University of Pennsylvania, suggests that nisin's five thioether rings may turn out to be golden "in the never-ending search for blockbuster antibiotics."


'"/>

Source:University of Illinois at Urbana-Champaign


Related biology news :

1. Creationism is not science ?making the case for Darwin at UCL
2. Researchers make gains in understanding antibiotic resistance
3. Measuring hormone cuts antibiotic use in half in pneumonia patients
4. New book explains antibiotic resistance for a broad audience
5. Research on antibiotics receives historical recognition
6. Unusual antibiotics show promise against deadly superbugs
7. Doctors should stop prescribing antibiotics for the common cold, review advises
8. Gaining ground in the race against antibiotic resistance
9. Researchers find how some antibiotics kill bacteria
10. Einstein researchers identify new way that bacteria develop resistance to antibiotics
11. Agricultural antibiotic use contributes to super-bugs in humans
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/9/2016)... Feb. 9, 2016 Aware, Inc. (NASDAQ: AWRE ), ... results for its fourth quarter and year ended December 31, 2015.  ... the fourth quarter of 2015 was $6.9 million, an increase of ... Operating income in the fourth quarter of 2015 was $2.6 million ... --> --> Higher revenue and ...
(Date:2/8/2016)... 2016 Worldcore is ... innovation for clients, comfort and unbeatable security, with ... --> Worldcore is the first EU-regulated ... comfort and unbeatable security, with a Voice Biometrics ... Worldcore is the first EU-regulated global payment ...
(Date:2/4/2016)... 4, 2016 The field of Human ... the most popular hubs of the biotechnology industry. ... huge studies of human microbiota, have garnered a ... the microbiome space has literally exploded in terms ... This report focuses on biomedical aspects of research, ...
Breaking Biology News(10 mins):
(Date:2/10/2016)... ... February 10, 2016 , ... ... Society of Pharmaceutical Engineering (ISPE) Rocky Mountain Chapter 21st Annual Vendor Exhibition on ... fill more than 100 tables for its annual event, which will run from ...
(Date:2/10/2016)... ... February 10, 2016 , ... PatientCrossroads announces ... the secure online PatientCrossroads platform, has exceeded both its one-year and overall recruitment ... PROMPT study, which seeks to advance understanding of the hereditary risks for certain ...
(Date:2/10/2016)... ... February 10, 2016 , ... Cenna Bioscience Inc., an emerging biopharmaceutical ... Alzheimer’s disease, announced today it has been selected to present at the Cavendish Global ... Palm Beach, Florida. The purpose of the Forum is to help family offices ...
(Date:2/9/2016)... , Feb. 9, 2016  Regenicin, Inc. (OTC ... specializing in the development and commercialization of regenerative ... tissues and organs, recently reported the Company,s operating ... quarter of 2016. Lonza America , ... 2015 fiscal year in the process of consummating ...
Breaking Biology Technology: